References
1 European Commission. Roadmap. https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12154-Europe-s-Beating-Cancer-Plan (accessed 18 June 2020).
2 EU Parliament (2018). Vaccine hesitancy and drop in vaccination rates in Europe: European Parliament resolution of 19 April 2018 on vaccine hesitancy and the drop in vaccination rates in Europe (2017/2951(RSP)).
3 WHO Europe (2018). Strategy on the health and well-being of men in the WHO European Region. Regional Committee for Europe; Rome, Italy, 17-20 September.www.euro.who.int/__data/assets/pdf_file/0003/378165/68wd12e_MensHealthStrategy_180480.pdf?ua=1.
4 WHO (2019). Draft: Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem. https://www.who.int/docs/default-source/documents/cervical-cancer-elimination-draft-strategy.pdf?sfvrsn=380979d6_4
5 de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer 2017;141:664-670.
6 Chido-Amajuoyi OG, Domgue JF, Obi-Jeff C. A call for the introduction of gender-neutral HPV vaccination to national immunisation programmes in Africa. The Lancet Global Health 2019;7(1):E20-E21. doi: 10.1016/S2214-109X(18)30405-4.
7 International Agency for Research on Cancer (IARC)’s Monographs on the identification of carcinogenic hazards to humans. List of classified agents, Volumes 1-125: https://monographs.iarc.fr/agents-classified-by-the-iarc/ (accessed 22 June 2020).
8 De Vuyst H, Clifford G, Li N, et al. HPV infection in Europe. European Journal of Cancer 2009;45(15):2632-9. doi: 10.1016/j.ejca.2009.07.019.
9 Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The Human Papillomavirus Infection in Men Study: Human Papillomavirus Prevalence and Type Distribution among Men Residing in Brazil, Mexico, and the United States. Cancer Epidemiology Biomarkers and Prevention 2008;17(8):2036-2043. doi: 10.1158/1055-9965.EPI-08-0151
10 King EM, Gilson R, Beddows S, et al. Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. British Journal of Cancer 2015;112(9):1585-93. doi: 10.1038/bjc.2015.90.
11 Sonawane K, Suk R, Chiao EY, et al. Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Annals of Internal Medicine 2017;167(10):714-724. doi: 10.7326/M17-1363
12 Chaturvedi AK. Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and Women. Journal of Adolescent Health 2010;46(4):S20-S26. doi: 10.1016/j.jadohealth.2010.01.016
13 de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer 2017;141:664-670.
14 CDC. How Many Cancers Are Linked with HPV Each Year? https://www.cdc.gov/cancer/hpv/statistics/cases.htm (accessed 8 July 2020).
15 EU Science Hub. 2020 Cancer incidence and mortality in EU-27 countries. https://ec.europa.eu/jrc/en/news/2020-cancer-incidence-and-mortality-eu-27-countries (accessed 12 August 2020).
16 Hartwig S, St Guily JL, Dominiak-Felden G, et al. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infectious Agents and Cancer 2017;12:19. doi: 10.1186/s13027-017-0129-6.
17 de Martel C, Plummer M, Vignat Jet al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer 2017;141(4):664-670. doi: 10.1002/ijc.30716.
18 Hartwig S, Syrjänen S, Dominiak-Felden G, et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012;12(30). doi:10.1186/1471-2407-12-30.
19 Jakobsen KK, Grønhøj C, Jensen DH, et al. Increasing incidence and survival of head and neck cancers in Denmark: a nation-wide study from 1980 to 2014. Acta Oncologica 2018;57:9,1143-1151, doi: 10.1080/0284186X.2018.1438657.
20 Van Dyne EA, Henley SJ, Saraiya M, et al. Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015. Morbidity and Mortality Weekly Report 2018;67:918–924. doi: 10.15585/mmwr.mm6733a2.
21 Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health 2020;8(2):E191-E203. doi: 10.1016/S2214-109X(19)30482-6.
22 Donne AJ, Keltie K, Cole H, et al. Prevalence and management of recurrent respiratory papillomatosis (RRP) in the UK: cross-sectional study. Clinical Otolaryngology 2017;42: 86-91. doi: 10.1111/coa.12683.
23 Woodhall SC, Jit M, Soldan K, et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sexually Transmitted Infections 2011;87(6):458-463. doi:10.1136/sextrans-2011-050073.
24 San Giorgi MRM, Aaltonen LM, Rihkanen H, et al. Quality of life of patients with recurrent respiratory papillomatosis. Laryngoscope 2017;127(8):1826-1831. doi:10.1002/lary.26413.
25 Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report 2019;68:698–702. doi: 10.15585/mmwr.mm6832a3.
26 Bosch FX, Robles C, Díaz M, et al. HPV-FASTER: Broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology 2016;13(2):119-132. doi:10.1038/nrclinonc.2015.146.
27 Nätverket Mot Gynekologisk Cancer. A Sweden free from cervical cancer. https://www.gyncancer.se/utrotalivmoderhalscancer/ (accessed 9 July 2020).
28 Rodriguez AM, Zeybek B, Vaughn M et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study. Cancer 2020;126:1656-1667. doi: 10.1002/cncr.32700.
29 Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study BMJ 2019; 365:l1161. doi: 10.1136/bmj.l1161.
30 Kjaer SK, Nygård M, Sundström K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine 2020;23:100401. doi: 10.1016/j.eclinm.2020.100401.
31 Wangu Z, Hsu KK. Impact of HPV vaccination on anogenital warts and respiratory papillomatosis. Human Vaccines and Immunotherapeutics. 2016;12(6):1357-62. doi: 10.1080/21645515.2016.1172754.
32 Shapiro N. FDA Approves HPV Vaccine Gardasil as Throat Cancer Prevention. 17 June 2020. https://www.forbes.com/sites/ninashapiro/2020/06/17/fda-approves-hpv-vaccine-gardasil-as-throat-cancer-prevention/#216f793f207c (accessed 9 July 2020).
33 Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Global Health 2016; 4: e453–63. doi: 10.1016/S2214-109X(16)30099-7.
34 McRee AL, Katz ML, Paskett ED, et al. HPV vaccination among lesbian and bisexual women: Findings from a national survey of young adults. Vaccine 2014;32(37):4736-42. doi: 10.1016/j.vaccine.2014.07.001.
35 Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. International Journal of Cancer 2015;136(12):2752-60. doi: 10.1002/ijc.29082
36 Best SR, Niparko KJ, Pai SI. Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers. Otolaryngologic Clinics of North America 2012;45(4):807-22. doi: 10.1016/j.otc.2012.04.005.
37 Elfström KM, Lazzarato F, Franceschi S, et al. Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. The Journal of Infectious Diseases 2015;213(2):199–205. doi: 10.1093/infdis/jiv368.
38 Vänskä S, Luostarinen T, Baussano I, et al. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. The Journal of Infectious Diseases 2020. doi: 10.1093/infdis/jiaa099.
39 vaccines in EU countries: focus on 9-valent HPV vaccine and vaccination of boys and people living with HIV. Stockholm: ECDC; 2019. https://ecdc.europa.eu/sites/portal/files/documents/hpv-public-consultation-3-April.pdf.
40 Joint Committee on Vaccination and Immunisation (2018). Statement on HPV vaccination. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/726319/JCVI_Statement_on_HPV_vaccination_2018.pdf
41 Siebert U, Sroczynski G, Baker P, et al. Framework for Evidence Assessment Based on Grade and Application to HPV Vaccination in Males in the European Health Care Context. Value in Health 2013;16(7):A327.
42 European Parliamentary Forum for Sexual & Reproductive Rights. Cervical Cancer Prevention Policy Atlas (January 2020). https://www.epfweb.org/node/553 (accessed 15 June 2020); HPV Information Centre. https://www.hpvcentre.net/ (accessed 15 June 2020); and other sources accessed via Google.
43 Zeitoun j-D, Duclos A, de Parades V, et al. Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018. Human Vaccines & Immunotherapeutics 2020. doi: 10.1080/21645515.2020.1756151.
44 Edelstein M, Iyanger N, Hennessy N, et al. Implementation and evaluation of the human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM), England, April 2016 to March 2017. Euro Surveillance 2019;24(8):1800055. doi:10.2807/1560-7917.
45 Campari C, Fedato C, Petrelli A, et al. HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs. Infectious Agents and Cancer 2015;10:14. doi:10.1186/s13027-015-0009-x
46 WHO. Weekly epidemiological record 2019;94(47):541-560. https://apps.who.int/iris/bitstream/handle/10665/329962/WER9447-eng-fre.pdf?ua=1 (accessed 16 June 2020).
47 Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Global Health 2016; 4: e453–63. doi: 10.1016/S2214-109X(16)30099-7.
48 MSD (2018). Variation in uptake of the HPV National Immunisation Programme (MSD, UK).
49 de Casadevante VF, Cuesta JG, Cantarero-Arévalo L, et al. Determinants in the Uptake of the Human Papillomavirus Vaccine: A Systematic Review Based on European Studies. Frontiers in Oncology 2015;5:141. doi: 10.3389/fonc.2015.00141.
50 Ciavattini A, Delli Carpini G, Giannella L, et al. European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. International Journal of Gynecologic Cancer 2020. doi: 10.1136/ijgc-2020-001617.
51 Department of Health and Social Care. Joint Committee on Vaccination and Immunisation: statement on the delivery of the HPV vaccine. 16 July 2020. https://www.gov.uk/government/publications/delivery-of-the-hpv-vaccine-and-impact-of-school-closures-statement-from-the-jcvi/joint-committee-on-vaccination-and-immunisation-statement-on-the-delivery-of-the-hpv-vaccine (accessed 12 August 2020).
52 Lincolnshire Community Health Services NHS Trust. Don’t miss out on your child’s HPV vaccination - give your consent today! https://www.lincolnshirecommunityhealthservices.nhs.uk/latest-news/dont-miss-out-your-childs-hpv-vaccination-give-your-consent-today (accessed 8 July 2020).
53 Calo WA, Gilkey MB, Shah P, et al. Parents’ willingness to get human papillomavirus vaccination for their adolescent children at a pharmacy. Preventive Medicine 2017;99:251-256. doi: 10.1016/j.ypmed.2017.02.003.
54 Jansen EEL, Zielonke N, Gini A, et al. Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review. European Journal of Cancer 2020;127:207-223. doi: 10.1016/j.ejca.2019.12.013.
55 Day AT, Fakhry C, Tiro JA, et al. Considerations in Human Papillomavirus-Associated Oropharyngeal Cancer Screening: A Review. JAMA Otolaryngology Head and Neck Surgery 2020. doi: 10.1001/jamaoto.2019.4811.
56 Wieland U, Kreuter A. Anal cancer risk: HPV-based cervical screening programmes. The Lancet 2019;19(8):799-800. doi: 10.1016/S1473-3099(19)30296-8.
57 Alqhtani N, Alenazi A, Nasyam FA, et al. Role of the dentist in early detection of oral cancer. Journal of International Oral Health 2019;11(2)66-69. doi: 10.4103/jioh.jioh_303_18.
58 Gellrich N-C, Suarez-Cunqueiro MM, Bremerich A, et al. Characteristics of oral cancer in a central European population: defining the dentist’s role. Journal of the American Dental Association 2003;134(3):307-14. doi: 10.14219/jada.archive.2003.0159.
59 European Parliamentary Forum for Sexual & Reproductive Rights. Cervical Cancer Prevention Policy Atlas (January 2020). https://www.epfweb.org/node/553 (accessed 15 June 2020).
60 European Commission (2015). European guidelines for quality assurance in cervical cancer screening. Second Edition. https://op.europa.eu/en/publication-detail/-/publication/a41a4c40-0626-4556-af5b-2619dd1d5ddc (accessed 16 June 2020).
61 Chrysostomou AC, Stylianou DC, Constantinidou A, et al.. Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses 2018;10(12):729. doi: 10.3390/v10120729.
62 European Parliamentary Forum for Sexual & Reproductive Rights. Cervical Cancer Prevention Policy Atlas (January 2020). https://www.epfweb.org/node/963 (accessed 15 June 2020).
63 European Parliamentary Forum for Sexual & Reproductive Rights. Cervical Cancer Prevention Policy Atlas (January 2020). https://www.epfweb.org/node/963 (accessed 15 June 2020).
64 Eurostat. Healthcare activities statistics – preventive services. https://ec.europa.eu/eurostat/statistics-explained/index.php/Healthcare_activities_statistics_-_preventive_services#Cervical_cancer_screening.
65 European Commission (2015). European guidelines for quality assurance in cervical cancer screening. Second Edition. https://op.europa.eu/en/publication-detail/-/publication/a41a4c40-0626-4556-af5b-2619dd1d5ddc (accessed 16 June 2020).
66 Chrysostomou AC, Stylianou DC, Constantinidou A, et al. Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses 2018;10(12):729. doi: 10.3390/v10120729.
67 Yeh PT, Kennedy CE, de Vuyst H, et al. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Global Health 2019 May;4(3):e001351. doi: 10.1136/bmjgh-2018-001351.
68 Gupta S, Palmer C, Bik EM, et al. Self-Sampling for Human Papillomavirus Testing: Increased Cervical Cancer Screening Participation and Incorporation in International Screening Programs. Frontiers in Public Health 2018;6:77. doi:10.3389/fpubh.2018.00077
69 Brewer N, Bartholomew K, Maxwell A. et al. Comparison of two invitation-based methods for human papillomavirus (HPV) self-sampling with usual care among un- and under-screened Māori, Pacific and Asian women: study protocol for a randomised controlled community trial to examine the effect of self-sampling on participation in cervical-cancer screening. BMC Cancer 2019;19(1198). doi: 10.1186/s12885-019-6401-y.
70 Ciavattini A, Delli Carpini G, Giannella L, et al. European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. International Journal of Gynecologic Cancer 2020. doi: 10.1136/ijgc-2020-001617.
71 Gultekin M, Karaca MZ, Kucukyildiz I, et al. Mega HPV laboratories for cervical cancer control: challenges and recommendations from a case study of Turkey. Papillomavirus Research 2019;7:118-22. doi: 10.1016/j.pvr.2019.03.002.
72 Peeters E, Cornet K, Devroey D, et al. Efficacy of strategies to increase participation in cervical cancer screening: GPs offering self-sampling kits for HPV testing versus recommendations to have a pap smear taken - A randomised controlled trial. Papillomavirus Research 2020;9:100194. doi: 10.1016/j.pvr.2020.100194.
73 Iftner T, Neis KJ, Castanon A, et al. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany. Journal of Clinical Microbiology 2019;57(1):e01177-18. doi:10.1128/JCM.01177-18
74 Razzaghi H, Saraiya M, Thompson TD, et al. Five-year relative survival for human papillomavirus-associated cancer sites. Cancer 2018;124(1):203-211. doi:10.1002/cncr.30947.
75 OECD/EU (2018). Health at a Glance: Europe 2018: State of Health in the EU Cycle. OECD Publishing, Paris. https://doi.org/10.1787/health_glance_eur-2018-en (accessed 16 June 2020).
76 Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018 Mar 17;391(10125):1023-1075.
77 Information Network on Rare Cancers (RARECAREnet) project’s online analysis tool: http://rarecarenet.eu/analysis.php (accessed 22 June 2020; data collected: age-standardised five-year survival for anal squamous cell carcinoma).
78 European Cancer Information System (ECIS). https://ecis.jrc.ec.europa.eu/index.php (accessed 22 June 2020).
79 Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. International Journal of Gynecological Cancer 2018;28(4):641-655. doi: 10.1097/IGC.0000000000001216.
80 Glynne-Jones R, Nilsson PJ, Aschele C, et al. Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiotherapy and Oncology 2014;111(3):330-339. doi: 10.1016/j.radonc.2014.04.013.
81 National Cancer Institute. Head and Neck Cancer – Health Professional Version. https://www.cancer.gov/types/head-and-neck/hp (accessed 17 June 2020).
82 Mehanna H, Evans M, Beasley M, et al. Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. The Journal of Laryngology and Otology 2016;130(S2):S90-S96. doi:10.1017/S0022215116000505.
83 Van Poppel H, Watkin NA, Osanto S, et al. Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Genitourinary Cancers 2013;24(S6):VI115-VI124. doi: 10.1093/annonc/mdt286.
84 Pfaendler KS, Wenzel L, Mechanic MB, et al. Cervical cancer survivorship: long-term quality of life and social support. Clinical Therapeutics 2015:37(1):39-48. doi: 10.1016/j.clinthera.2014.11.013.
85 Michaelson SH, Grønhøj C, Michaelsen JH, et al. Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients. European Journal of Cancer 2017;78:91-102. doi: 10.1016/j.ejca.2017.03.006.
86 Sodergren SC, Gilbert A, Darlington AS, et al. Anal Cancer: Putting Health-Related Quality of Life at the Forefront. Clinical Oncology 2019;31(2):69-71. doi: 10.1016/j.clon.2018.10.010.
87 Suppli CH, Hansen ND, Rasmussen M, et al. Decline in HPV-vaccination uptake in Denmark – the association between HPV-related media coverage and HPV-vaccination. BMC Public Health 2018;18:1360. doi: 10.1186/s12889-018-6268-x.
88 Wellcome Trust (2019). Wellcome Global Monitor How does the world feel about science and health? https://wellcome.ac.uk/sites/default/files/wellcome-global-monitor-2018.pdf
89 Karafillakis E, Simas C, Jarrett C, et al. HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe Human Vaccines & Immunotherapeutics 2019;15(7-8):1615-1627. doi: 10.1080/21645515.2018.1564436.
90 Lechner M, Jones OS, Breeze CE, et al. Gender-neutral HPV vaccination in the UK, rising male oropharyngeal cancer rates, and lack of HPV awareness. The Lancet Infectious Diseases 2019;19(2):131-132. doi: 10.1016/s1473-3099(18)30802-8
91 IPSOS (2019). EU HPV Consumer Awareness Study. https://www.ipsos.com/sites/default/files/ct/news/documents/2019-05/eu-hpv-consumer-awareness-study-updated_0.pdf (accessed 14 August 2020).
92 European Parliamentary Forum for Sexual & Reproductive Rights. Cervical Cancer Prevention Policy Atlas (January 2020). https://www.epfweb.org/node/963 (accessed 15 June 2020); HPV Information Centre. https://www.hpvcentre.net/ (accessed 15 June 2020).
93 Zhang S. We Don’t Even Have a COVID-19 Vaccine, and Yet the Conspiracies are Here. The Atlantic 2020; May 4. https://www.theatlantic.com/science/archive/2020/05/covid-19-vaccine-skeptics-conspiracies/611998/ (accessed 17 June 2020).
94 Waller J, Forster A, Ryan M, et al. Decision-making about HPV vaccination in parents of boys and girls: A population-based survey in England and Wales. Vaccine 2020;38(5):1040-1047. doi: 10.1016/j.vaccine.2019.11.046.
95 Karafillakis E, Dinca I, Apfel F, et al. Vaccine hesitancy among healthcare workers in Europe: A qualitative study. Vaccine 2016;34(41):5013-5020. doi: 10.1016/j.vaccine.2016.08.029.
96 Sherman SM, Cohen CR, Denison HJ et al. A survey of knowledge, attitudes and awareness of the human papillomavirus among healthcare professionals across the UK, European Journal of Public Health 2020;30(1):10-16, doi: 10.1093/eurpub/ckz113.
97 Couespel N, Price R (2020). Strengthening Europe in the fight against cancer: Going further, faster. https://www.europarl.europa.eu/RegData/etudes/STUD/2020/642388/IPOL_STU(2020)642388_EN.pdf (accessed 19 August 2020).
